The past, presence and future of ADMA in nephrology

Nephrologie et Therapeutique

Volumn 3, Issue 2, 2007, Pages 47-54

  Kielstein, Jan T ^a   Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Asymmetric dimethylarginine (ADMA); Nephrology; Symmetrical dimethylarginine (SDMA)

Indexed keywords

AMLODIPINE; ENALAPRIL; EPROSARTAN; ESTROGEN; GESTAGEN; METFORMIN; N(G),N(G) DIMETHYLARGININE; OLMESARTAN; PERINDOPRIL; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN; THYROXINE; VALSARTAN; ZOFENOPRIL; ARGININE; DRUG DERIVATIVE; ENZYME INHIBITOR; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; HEART LEFT VENTRICLE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POPULATION RESEARCH; SHORT SURVEY; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; KIDNEY DISEASE; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; URINE;

ARGININE; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; NITRIC OXIDE SYNTHASE; RISK FACTORS;

EID: 34247101940     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2007.02.002     Document Type: Short Survey

References (80)

1. Kielstein A., Tsikas D., Galloway G.P., and Mendelson J.E. Asymmetric dimethylarginine (ADMA) - A modulator of nociception in opiate tolerance and addiction?. Nitric Oxide (2007) [in press]
2. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1455-1459
3. Dayoub H., Achan V., Adimoolam S., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047
4. Leiper J., Nandi M., Torondel B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13 (2007) 198-203
5. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 109 (2004) 1813-1818
6. Jacobi J., Sydow K., Von D.G., et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111 (2005) 1431-1438
7. Thum T., Tsikas D., Stein S., et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J. Am. Coll. Cardiol. 46 (2005) 1693-1701
8. Kielstein J.T., and Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?. Am. J. Kidney Dis. 46 (2005) 186-202
9. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
10. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
11. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 (2006) 2024-2029
12. Kielstein J.T., Simmel S., Bode-Boger S.M., et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res. 27 (2004) 143-147
13. Zoccali C., Benedetto F.A., Maas R., et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13 (2002) 490-496
14. Furuki K., Adachi H., Matsuoka H., et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery An epidemiological study. Atherosclerosis 191 1 (2007) 206-210
15. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62 (2002) 339-345
16. Kielstein J.T., Bode-Boger S.M., Hesse G., et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1414-1418
17. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clin. Chem. 43 (2007) 517-526
18. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97 (2005) e53-e59
19. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
20. Kakimoto Y., and Akazawa S. Isolation and identification of N-G,N-G- and N-G,N′-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 245 (1970) 5751-5758
21. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264 (1989) 10205-10209
22. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
23. Vanholder R., De S.R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63 (2003) 1934-1943
24. Lindner A., Charra B., Sherrard D.J., and Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290 (1974) 697-701
25. Schmidt R.J., Yokota S., Tracy T.S., Sorkin M.I., and Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am. J. Physiol. 276 (1999) F794-F797
26. Cross J.M., Donald A., Vallance P.J., et al. Dialysis improves endothelial function in humans. Nephrol. Dial. Transplant. 16 (2001) 1823-1829
27. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10 (1999) 594-600
28. MacAllister R.J., Rambausek M.H., Vallance P., et al. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol. Dial. Transplant. 11 (1996) 2449-2452
29. Hand M.F., Haynes W.G., and Webb D.J. Hemodialysis and l-arginine, but not d-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 53 (1998) 1068-1077
30. Joannides R., Bakkali E.H., Le R.F., et al. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol. Dial. Transplant. 12 (1997) 2623-2628
31. Kari J.A., Donald A.E., Vallance D.T., et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 52 (1997) 468-472
32. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 13 (2002) 170-176
33. Uchida H.A., Nakamura Y., Kaihara M., et al. Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy. Nephrol. Dial. Transplant. 21 (2006) 3475-3480
34. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 765-769
35. Caglar K., Yilmaz M.I., Sonmez A., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 70 4 (2006) 781-787
36. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16 (2005) 2449-2455
37. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 16 (2005) 2456-2461
38. Anderstam B., Katzarski K., and Bergstrom J. Serum levels of NG, NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J. Am. Soc. Nephrol. 8 (1997) 1437-1442
39. Schmidt R.J., Domico J., Samsell L.S., et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am. J. Kidney Dis. 34 (1999) 228-234
40. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. Clin. Nephrol. 62 (2004) 295-300
41. Bergamini S., Vandelli L., Bellei E., et al. Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 11 (2004) 273-278
42. Kalousova M., Kielstein J.T., Hodkova M., et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif. 24 (2006) 439-444
43. Schroder M., Riedel E., Beck W., Deppisch R.M., and Pommer W. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int. Suppl. 78 (2001) S19-S24
44. Beerenhout C.H., Luik A.J., Jeuken-Mertens S.G., et al. Pre-dilution on-line haemofiltration vs. low-flux haemodialysis: a randomized prospective study. Nephrol. Dial. Transplant. 20 (2005) 1155-1163
45. Chan C.T., Harvey P.J., Boger R., Pierratos A., and Floras J.S. Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2685-2686
46. Carello K.A., Whitesall S.E., Lloyd M.C., Billecke S.S., and D'Alecy L.G. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H209-H216
47. Billecke S.S., Kitzmiller L.A., Northrup J.J., et al. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 291 4 (2006) H1788-H1796
48. Wahbi N., Dalton R.N., Turner C., et al. Dimethylarginines in chronic renal failure. J. Clin. Pathol. 54 (2001) 470-473
49. Morimoto H., Nakao K., Fukuoka K., et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol. Dial. Transplant. 20 (2005) 2775-2782
50. White R., and Ram S. Peritoneal dialysis solution attenuates microvascular leukocyte adhesion induced by nitric oxide synthesis inhibition. Adv. Perit. Dial. 12 (1996) 53-56
51. Fleck C., Schweitzer F., Karge E., Busch M., and Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin. Chim. Acta 336 (2003) 1-12
52. Yilmaz M.I., Saglam M., Caglar K., et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 80 (2005) 1660-1666
53. Cross J.M., Donald A.E., Kharbanda R., et al. Acute administration of l-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 60 (2001) 2318-2323
54. Schulman S.P., Becker L.C., Kass D.A., et al. l-Arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295 (2006) 58-64
55. Ito A., Egashira K., Narishige T., Muramatsu K., and Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn. Circ. J. 65 (2001) 775-778
56. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am. J. Hypertens. 15 (2002) 590-593
57. Napoli C., Sica V., de Nigris F., et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 148 (2004) e5
58. Fliser D., Wagner K.K., Loos A., Tsikas D., and Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16 (2005) 1135-1140
59. Aslam S., Santha T., Leone A., and Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 70 (2006) 2109-2115
60. Asagami T., Abbasi F., Stuelinger M., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51 (2002) 843-846
61. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
62. Wakino S., Hayashi K., Tatematsu S., et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens. Res. 28 (2005) 255-262
63. Lu T.M., Ding Y.A., Leu H.B., et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 94 (2004) 157-161
64. Post M.S., Verhoeven M.O., van der Mooren M.J., et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J. Clin. Endocrinol. Metab. 88 (2003) 4221-4226
65. Teerlink T., Neele S.J., De Jong S., Netelenbos J.C., and Stehouwer C.D. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin. Sci. (Lond.) 105 (2003) 67-71
66. Holden D.P., Cartwright J.E., Nussey S.S., and Whitley G.S. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 108 (2003) 1575-1580
67. Ozcan O., Cakir E., Yaman H., et al. The effects of C on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin. Endocrinol. (Oxf.) 63 (2005) 203-206
68. Hermenegildo C., Medina P., Peiro M., et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J. Clin. Endocrinol. Metab. 87 (2002) 5636-5640
69. Sydow K., and Munzel T. ADMA and oxidative stress. Atheroscler. Suppl. 4 (2003) 41-51
70. Holven K.B., Haugstad T.S., Holm T., et al. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br. J. Nutr. 89 (2003) 359-363
71. Saran R., Novak J.E., Desai A., et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol. Dial. Transplant. 18 (2003) 2415-2420
72. Sydow K., Schwedhelm E., Arakawa N., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc. Res. 57 (2003) 244-252
73. Scalera F., Kielstein J.T., Martens-Lobenhoffer J., et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J. Am. Soc. Nephrol. 16 (2005) 892-898
74. Murray-Rust J., Leiper J., McAlister M., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat. Struct. Biol. 8 (2001) 679-683
75. Matsuguma K., Ueda S., Yamagishi S., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J. Am. Soc. Nephrol. 17 (2006) 2176-2183
76. Hu T., Chouinard M., Cox A.L., et al. FXR agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281 52 (2006) 39831-39838
77. Kielstein J.T., Salpeter S.R., Bode-Boeger S.M., Cooke J.P., and Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol. Dial. Transplant. 21 (2006) 2446-2451
78. Bode-Boger S.M., Scalera F., Kielstein J.T., et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J. Am. Soc. Nephrol. 17 (2006) 1128-1134
79. Manolio T. Novel risk markers and clinical practice. N. Engl. J. Med. 349 (2003) 1587-1589
80. Kielstein J.T., Frolich J.C., Haller H., and Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?. Nephrol. Dial. Transplant. 16 (2001) 1742-1745